nu6102 and palbociclib

nu6102 has been researched along with palbociclib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gucký, T; Hendrychová, D; Jorda, R; Kryštof, V; Řezníčková, E; Voller, J	1
Bacevic, K; Boszonyik, B; Fisher, D; Hochberg, ME; Krasinska, L; Noble, R; Prieto, S; Soffar, A; Vincent, C; Wael Ammar, O	1

Other Studies

2 other study(ies) available for nu6102 and palbociclib

Article	Year
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? Journal of medicinal chemistry, 2018, 10-25, Volume: 61, Issue:20 Topics: Cell Cycle; Cyclin-Dependent Kinases; HCT116 Cells; Humans; Protein Kinase Inhibitors; Quinolines; Thiazoles	2018
Spatial competition constrains resistance to targeted cancer therapy. Nature communications, 2017, 12-08, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Models, Biological; Neoplasms; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; RNA, Small Interfering; Spheroids, Cellular; Tumor Burden; Xenograft Model Antitumor Assays	2017

Article

Year

How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?

Journal of medicinal chemistry, 2018, 10-25, Volume: 61, Issue:20

Topics: Cell Cycle; Cyclin-Dependent Kinases; HCT116 Cells; Humans; Protein Kinase Inhibitors; Quinolines; Thiazoles

2018

Spatial competition constrains resistance to targeted cancer therapy.

Nature communications, 2017, 12-08, Volume: 8, Issue:1

Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Models, Biological; Neoplasms; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; RNA, Small Interfering; Spheroids, Cellular; Tumor Burden; Xenograft Model Antitumor Assays

2017